Cover ImageSALE
市場調查報告書

腎上腺素注射器的全球市場:2017年∼2021年

Global Epinephrine Autoinjector Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 282669
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
腎上腺素注射器的全球市場:2017年∼2021年 Global Epinephrine Autoinjector Market 2017-2021
出版日期: 2017年02月17日 內容資訊: 英文 84 Pages
簡介

腎上腺素,是過敏性反應症候群治療的第一線醫藥品,成為緊急狀態時的救命藥。腎上腺素注射器在1980年代已經確實證明有助於維持重病的過敏患者的生命。1987年EpiPen由FDA (美國食品藥物管理局) 認證以來,技術開發持續進行。腎上腺素注射器的全球市場,預計從2017年到2021年,以14.58%的年複合成長率 (CAGR) 擴大。

本報告提供全球腎上腺素注射器市場相關分析,產品概要和市場基本結構,市場規模趨勢 (今後5年的預測值),各劑量、各年齡層、各終端用戶、各地區的詳細趨勢,推動、阻礙市場要素與其影響力,主要企業簡介,今後的市場機會等調查評估。

第1章 摘要整理

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要
  • 腎上腺素注射器:概要

第5章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第6章 各劑量的市場區隔

  • 劑量是0.15克的情況
  • 劑量是0.30克的情況
  • 劑量是0.5克的情況

第7章 各年齡層的市場區隔

第8章 各終端用戶的市場區隔

  • 醫院、診療所
  • 個人

第9章 地區區分

  • 南北美洲市場
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 亞太地區市場

第10章 推動市場要素

  • 過敏患病人數的增加
  • 技術進步
  • 行銷策略

第11章 推動因素的影響力

第12章 市場課題

  • 產品回收和法規上的課題
  • 替代的產品的存在
  • 成本高

第13章 推動因素、課題的影響力

第14章 市場趨勢

  • 實驗的產品的銷售
  • 腎上腺素注射器的認知度的上升
  • 患者支援計劃

第15章 供應商環境

  • 競爭方案
  • 近幾年的主要趨勢
  • 主要供應商的各個地區的存在感分析

第16章 主要供應商分析

  • ALK-Abello
  • Impax Laboratories
  • Lincoln Medical
  • Mylan
  • 其他卓越供應商

第17章 附錄

  • 簡稱集

第18章 關於Technavio

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR12027

About epinephrine autoinjector

Epinephrine is among the first line of treatment drugs for anaphylactic conditions and is considered a life-saving drug during emergencies. Epinephrine autoinjectors have proved to be a life savior for people with severe allergies from as early as the 1980s. The global epinephrine autoinjector market has been witnessing continuous technological innovations and developments over the years, after the first FDA approval of EpiPen in 1987.

Technavio's analysts forecast the global epinephrine autoinjector market to grow at a CAGR of 14.58% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global epinephrine autoinjector market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of various epinephrine autoinjectors to key end-users such as hospitals, clinics, and individuals.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Epinephrine Autoinjector Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ALK-Abello
  • Impax Laboratories
  • Lincoln Medical
  • Mylan

Other Prominent Vendors

  • Adamis Pharmaceuticals
  • Antares Pharma
  • Emerade
  • Hospira
  • Kaleo Pharma
  • Teva Pharmaceutical Industries

Market driver

  • Increasing prevalence of allergies
  • For a full, detailed list, view our report

Market challenge

  • Product recalls and regulatory issues
  • For a full, detailed list, view our report

Market trend

  • Tentative product launches
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Epinephrine autoinjector: Overview

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by dosage

  • Global epinephrine autoinjector market by 0.15gm dosage
  • Global epinephrine autoinjector market by 0.30gm dosage
  • Global epinephrine autoinjector market by 0.5gm dosage

PART 07: Market segmentation by age group

PART 08: Market segmentation by end-user

  • Hospitals and clinics
  • Individuals

PART 09: Geographical segmentation

  • Epinephrine autoinjector market in the Americas
  • Epinephrine autoinjector market in EMEA
  • Epinephrine autoinjector market in APAC

PART 10: Market drivers

  • Increasing prevalence of allergies
  • Technological advances
  • Marketing strategies

PART 11: Impact of drivers

PART 12: Market challenges

  • Product recalls and regulatory issues
  • Presence of substitutes
  • High cost

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Tentative product launches
  • Growing awareness about epinephrine autoinjectors
  • Patient assistance programs

PART 15: Vendor landscape

  • Competitive scenario
  • Key news
  • Geographical presence of key vendors

PART 16: Key vendor analysis

  • ALK-AbellA³
  • Impax Laboratories
  • Lincoln Medical
  • Mylan
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global epinephrine autoinjector market: Analysis
  • Exhibit 03: Key buying criteria for epinephrine autoinjectors
  • Exhibit 04: Buying criteria for epinephrine autoinjectors
  • Exhibit 05: Key factors influencing development of epinephrine autoinjectors
  • Exhibit 06: Allergy statistics
  • Exhibit 07: Market overview: Global epinephrine autoinjector market
  • Exhibit 08: Global epinephrine autoinjector market ($ millions)
  • Exhibit 09: Global epinephrine autoinjector market analysis: Developed and developing markets
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Global epinephrine autoinjector market segmentation by dosage 2016
  • Exhibit 12: Global epinephrine autoinjector market segmentation by dosage 2020
  • Exhibit 13: Global epinephrine autoinjector market by 0.15gm dosage 2016-2021 ($ millions)
  • Exhibit 14: Global epinephrine autoinjector market by 0.30gm dosage 2016-2021 ($ millions)
  • Exhibit 15: Global epinephrine autoinjector market by 0.5gm dosage 2016-2021 ($ millions)
  • Exhibit 16: Global epinephrine autoinjector market segmentation by dosage 2016-2021 (%)
  • Exhibit 17: Global epinephrine autoinjector market segmentation by dosage 2016-2021 ($ millions)
  • Exhibit 18: Global epinephrine autoinjector market by age group 2016
  • Exhibit 19: Global epinephrine autoinjector market by end-user 2016
  • Exhibit 20: Global epinephrine autoinjector market segmentation by geography 2016
  • Exhibit 21: Global epinephrine autoinjector market segmentation by geography 2021
  • Exhibit 22: Epinephrine autoinjector market in the Americas 2016-2021 ($ millions)
  • Exhibit 23: Market overview: Americas
  • Exhibit 24: Epinephrine autoinjector market overview: US
  • Exhibit 25: Epinephrine autoinjector market in the US 2016-2021 ($ millions)
  • Exhibit 26: Market overview: EMEA
  • Exhibit 27: Epinephrine autoinjector market in EMEA 2016-2021 ($ millions)
  • Exhibit 28: Market overview: APAC
  • Exhibit 29: Epinephrine autoinjector market in APAC 2016-2021 ($ millions)
  • Exhibit 30: Global epinephrine autoinjector market segmentation by geography 2016-2021 ($ millions)
  • Exhibit 31: Global epinephrine autoinjector market segmentation by geography 2016-2021 (%)
  • Exhibit 32: Allergy statistics
  • Exhibit 33: Technological advances
  • Exhibit 34: Marketing strategies of Mylan
  • Exhibit 35: Impact of drivers
  • Exhibit 36: Product recalls
  • Exhibit 37: Alternatives of epinephrine autoinjectors in the market
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Competitive structure of the global epinephrine autoinjector market
  • Exhibit 40: Market penetration of various epinephrine autoinjector manufacturers globally (2016)
  • Exhibit 41: Strategic success factors of companies in global epinephrine autoinjector market 2016
  • Exhibit 42: Share of vendors in global epinephrine autoinjector market 2016
  • Exhibit 43: Regional analysis of key vendors
  • Exhibit 44: Key highlights of ALK-AbellA³
  • Exhibit 45: ALK-AbellA³ strength assessment
  • Exhibit 46: ALK-AbellA³ strategy assessment
  • Exhibit 47: ALK-AbellA³ opportunity assessment
  • Exhibit 48: Key highlights of Impax Laboratories
  • Exhibit 49: Impax Laboratories strength assessment
  • Exhibit 50: Impax Laboratories strategy assessment
  • Exhibit 51: Impax Laboratories opportunity assessment
  • Exhibit 52: Lincoln Medical strength assessment
  • Exhibit 53: Lincoln Medical strategy assessment
  • Exhibit 54: Lincoln Medical opportunity assessment
  • Exhibit 55: Key highlights of Mylan
  • Exhibit 56: Mylan strength assessment
  • Exhibit 57: Mylan strategy assessment
  • Exhibit 58: Mylan opportunity assessment
Back to Top